Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Receivables for 8 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 60.79% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.0 million through Dec 2025, down 8.82% year-over-year, with the annual reading at $31.0 million for FY2025, 8.82% down from the prior year.
  • Change in Receivables for Q4 2025 was $33.8 million at Ultragenyx Pharmaceutical, up from -$5.4 million in the prior quarter.
  • The five-year high for Change in Receivables was $33.8 million in Q4 2025, with the low at -$10.1 million in Q1 2025.
  • Average Change in Receivables over 5 years is $5.3 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Change in Receivables crashed 955.56% in 2022, then skyrocketed 7700.0% in 2023.
  • Over 5 years, Change in Receivables stood at $3.1 million in 2021, then soared by 196.25% to $9.1 million in 2022, then crashed by 108.69% to -$790000.0 in 2023, then skyrocketed by 2763.54% to $21.0 million in 2024, then soared by 60.79% to $33.8 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $33.8 million, -$5.4 million, and $12.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.